In 25 clinical samples serum lidocaine concentrations fell from a mean of 6.5 ± 2.1 mg/L (mean ± SD) to 4.9 ± 1.8 mgIL(p < 0.001) when the blood sample was allowed to make contact with the stopper of the Vacutainer#{174} collection tube. In vitro experiments showed that this effect of the stopper occurred only with whole blood and was dependent on sample concentration. The plasma binding of lidocaine decreasedfrom a normal value of 56% ± 2.2 (mean ± SD)to 28% ± 2.2 (p < 0.001)when exposedto the Vacutainer stopper. We conclude that a chemical leached from such stoppers displaces lidocaine from its plasma-binding sites and that the drug is then redistributed 
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Materials and Methods

Patients' Samples
Blood sampleswerecollectedinto plastic syringes from patients and transferred to Vacutainer Tubes from which the red stopper had been removed. One aliquot was allowed to clot,while another aliquot was placed in a red-stoppered tube, allowed to contact the stopper, and clot. The two serum samples were assayed for lidocaine with one lot of EMIT5-cad (Syva Corp., Palo Alto, CA) reagents.
In Vitro Experiments
One hundred milliliters of whole blood from a normal volunteer receiving no medication was collected by direct venipuncture in a plastic syringe and immediately transferred to a glass tube containing 500 USP units of heparin. Lidocaine hydrochloride was added to give a final concentration of 3 g of lidocaine per milliliter of blood. Two-milliliter aliquots were then transferred to five glass-stoppered tubes, five greenstoppered Vacutainer Tubes, fivered-stoppered Vacutainer Tubes, and five red-stoppered Monojecte tubes (Sherwood Medical Industries, St. Louis, MO). The remaining blood was then centrifuged, and 1-mL aliquots of the plasma layer were added to various tubes, as described for whole blood. All tubes were then inverted 10 times and plasma obtained from the blood samples. All plasma samples were assayed for lidocaine with one lot of EMIT reagent.
The effect of increased concentrations of lidocaine(up to 12 izg/mL) added to blood collected in Vacutainer Tubes or in an all-glass system was also investigated in quadruplicate.
Plasma Binding
Plasma was obtained afterblood collection intoVacutainer Tubes or glass-stopperedtubes,and lidocainewas added to a final concentrationof 2 zg/mL. Five 1-mL samples of plasma from each collectionsystem were dialyzed against I mL of Sorensen's phosphate buffer (pH 7.38)at 37 #{176}C for 6 h by means of Teflon dialysis cellsand Spectrapor membranes (Spectrum Medical Industries,Los Angeles, CA). Lidocaine concentrationsin both plasma and bufferwere measured and calculated from appropriatestandard curves,and the per cent plasma binding was calculated.
Results
In the 25 clinical samples, exposure to the rubber stopper lowered lidocaine concentration in serum from 6.5 ± 2.1 tg/mL (mean ± SD) to 4.9 ± 1.8 zg/mL (p <0.001 by a paired t-test).
In the in vitro experiment, there was a significant reduction in the lidocaine concentration of plasma obtained from blood collected in the commercial tubes (Table 1 ).This was not seen when plasma was added to the tubes, which shows that er- The effect of increasing concentrations of lidocaine from 2 to 12 zg/mL in whole blood from Vacutainer Tubes or from an all-glass system on the subsequent lidocaine concentrations in plasma isshown in Figure 1 .With eithercollection system, increasingthe initial blood concentration produced a lesser increasein subsequent plasma concentration,which implies a decrease in the blood/plasma concentration ratio.Furthermore, the effect of using Vacutainer Tubes diminished progressively as whole blood concentration was increased, until there was no effect at 12 zg/mL.
Finally, when Vacutainer Tubes were used in blood collection, lidocaine binding in plasma fell significantly from a normal value of 56% ± 2.2 (mean ± SD) to 28% ± 2.2 (p <
by an unpaired t-test).
Discussion
Cotham and Shand (1) postulated that there was in some rubber stoppers a chemical that could leach intoblood and reduce the plasma binding of propranolol.The increasedfree drug could then partition with the drug bound to erythrocytes, which would lead to spuriously low plasma concentrations. The plasticizer tris(2-butoxyethyl) phosphate (TBEP) has been reported to be a contaminant in plasma collectedin Vacutainer Tubes (6) and identifiedas an inhibitorof drug binding to protein (7).Borga and coworkers subsequently have showed that TBEP-inhibited protein binding of aiprenololand imipramine isdue to a selectiveeffecton a,-acid glycoprotein,a probable major binding sitefor these basic ligands (2). In our studies we have found a similar phenomenon with lidocaine, with reduced binding in plasma confirmed.
It is therefore likelythat TBEP isthe compound that displaceslidocainefrom its binding sitesinplasma, although the relevant binding protein for lidocaine has not yet been identified (8). It is interesting that the magnitude of the effect of this phenomenon on lidocaine concentrations in plasma is very similar to the mean percentage effect on plasma propranolol concentration (28%) in plasma, calculated from the data of
Cotham and Shand (1), despite the fact that propranolol is 90-95% bound at therapeutic concentrations whereas lidocaine is only about 60% bound at a plasma concentration of 3 tg/mL (8). Presumably, the relative affinity of TBEP for the binding sites in plasma is much greater than the affinity of lidocaine.
Tucker and coworkers also showed that the binding of iidocaine varied from approximately 70% at 1 ig/mL of plasma to around 40% at 12 ig/mL (8). Theoretically, therefore, the effect of Vacutainer Tubes on the lidocaine concentration in plasma measured from a whole blood sample should fall with increasing lidocaine concentration, and we found this to be the case (Figure 1) . However, the percentage change of lidocaine concentration in plasma was still marked throughout the "therapeutic" range (1.5 to 5.0 ig/mL of plasma). The figure also shows that the concentration ratio of blood-toplasma increases with increasing lidocaine concentration in whole blood.
The enzyme immunoassay (EMIT) of lidocaine in serum or plasma has been shown to be rapid, specific, and sensitive and therefore particularly suitable for therapeutic monitoring
(9).
We feel it is important to emphasize that these advantages may be nullified and patients exposed to risk if clinical decisions are made on the basis of spuriously low concentrations of lidocaine in plasma or serum because of the use of certain types of commercially available collection tubes.
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